Question

A 58-year-old man with type 2 diabetes (eGFR 62 mL/min/1.73 m², BMI 31 kg/m²) is on metformin 1 g twice daily. HbA1c is 68 mmol/mol despite adherence. What is the most appropriate next-line add-on therapy to improve glycaemic control and CV risk?

Accepted Answer

Add an SGLT2 inhibitor

Answer

Add a sulfonylurea

Answer

Add a DPP-4 inhibitor

Answer

Add pioglitazone

Answer

Switch to insulin

Practice question

A 58-year-old man with type 2 diabetes (eGFR 62 mL/min/1.73 m², BMI 31 kg/m²) is on metformin 1 g twice daily. HbA1c is 68 mmol/mol despite adherence. What is the most appropriate next-line add-on therapy to improve glycaemic control and CV risk?